Joe M O'Sullivan
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.
Schoser B, van der Beek N, Broomfield A, Brusse E, Diaz-Manera J, Hahn A, Hundsberger T, Kornblum C, Kruijshaar M, Laforet P, Mengel E, Mongini T, Orlikowski D, Parenti G, Pijnappel W, Roberts M, Scherer T, Toscano A, Vissing J, O'Sullivan J, van Doorn P, Wenninger S, van der Ploeg A. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur J Neurol 2024; 31:e16383.
14.06.2024Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.
14.06.2024Eur J Neurol 2024; 31:e16383
Schoser Benedikt, van der Beek Nadine A M E, Broomfield Alexander, Brusse Esther, Diaz-Manera Jordi, Hahn Andreas, Hundsberger Thomas, Kornblum Cornelia, Kruijshaar Michelle E, Laforet Pascal, Mengel Eugen, Mongini Tiziana, Orlikowski David, Parenti Giancarlo, Pijnappel W W M Pim, Roberts Mark, Scherer Thomas, Toscano Antonio, Vissing John, O'Sullivan Joe M, van Doorn Pieter A, Wenninger Stephan, van der Ploeg Ans T
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Omlin A, Ryan C, Rubin M, Roach M, Reiter R, Pritchard C, Poon D, Parker C, Padhani A, O'Sullivan J, Ost P, Oh W, Murthy V, Murphy D, Mrabti H, Mottet N, Morris M, Saad F, Sade J, Zapatero A, van Oort I, Türkeri L, Tombal B, Taplin M, Sydes M, Sweeney C, Suzuki H, Steuber T, Sternberg C, Soule H, Smith M, Small E, Shore N, Scher H, Sartor O, Morgans A, Millman R, Evans C, Efstathiou E, Eeles R, Duran I, Drake C, de Bono J, Davis I, Clarke N, Chi K, Bristow R, Briganti A, Bossi A, Bjartell A, Beltran H, Beer T, Attard G, Fanti S, Feng F, Maluf F, Logothetis C, Leibowitz R, Khauli R, Kantoff P, Kanesvaran R, James N, Hussain M, Hofman M, Higano C, Heinrich D, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Gillessen S. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 2020; 77:508-547.
27.01.2020Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
27.01.2020Eur Urol 2020; 77:508-547
Omlin Aurelius, Ryan Charles J, Rubin Mark, Roach Mack, Reiter Robert E, Pritchard Colin C, Poon Darren M C, Parker Chris, Padhani Anwar R, O'Sullivan Joe M, Ost Piet, Oh William K, Murthy Vedang, Murphy Declan G, Mrabti Hind, Mottet Nicolas, Morris Michael J, Saad Fred, Sade Juan Pablo, Zapatero Almudena, van Oort Inge, Türkeri Levent, Tombal Bertrand, Taplin Mary-Ellen, Sydes Matthew R, Sweeney Christopher, Suzuki Hiroyoshi, Steuber Thomas, Sternberg Cora N, Soule Howard, Smith Matthew, Small Eric, Shore Neal, Scher Howard I, Sartor Oliver, Morgans Alicia K, Millman Robin, Evans Christopher P, Efstathiou Eleni, Eeles Ros, Duran Ignacio, Drake Charles G, de Bono Johann, Davis Ian D, Clarke Noel, Chi Kim N, Bristow Rob G, Briganti Alberto, Bossi Alberto, Bjartell Anders, Beltran Himisha, Beer Tomasz M, Attard Gerhardt, Fanti Stefano, Feng Felix Y, Maluf Fernando, Logothetis Chris, Leibowitz Raya, Khauli Raja B, Kantoff Philip, Kanesvaran Ravindran, James Nicolas, Hussain Maha, Hofman Michael S, Higano Celestia Tia S, Heinrich Daniel, Heidenreich Axel, Halabi Susan, Gleave Martin, Frydenberg Mark, Fizazi Karim, Gillessen Silke
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
Saad F, Carles J, Seger M, Reeves J, Wirth M, Miller K, Nilsson S, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clin Genitourin Cancer 2019; 17:348-355.e5.
31.05.2019Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
31.05.2019Clin Genitourin Cancer 2019; 17:348-355.e5
Saad Fred, Carles Joan, Seger Monica, Reeves John, Wirth Manfred, Miller Kurt, Nilsson Sten, O'Sullivan Joe M, Keizman Daniel, Heinrich Daniel, Gillessen Sommer Silke, Heidenreich Axel
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Heidenreich A, Nilsson S, Seger M, Reeves J, Miller K, Wirth M, Carles J, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC cancer 2019; 19:12.
07.01.2019Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
07.01.2019BMC cancer 2019; 19:12
Heidenreich Axel, Nilsson Sten, Seger Monica, Reeves John, Miller Kurt, Wirth Manfred, Carles Joan, O'Sullivan Joe M, Keizman Daniel, Heinrich Daniel, Gillessen Sommer Silke, Saad Fred
Consensus on molecular imaging and theranostics in prostate cancer
Fanti S, Montironi R, Ost P, O'Sullivan J, Padhani A, Schalken J, Scher H, Tombal B, van Moorselaar R, Van Poppel H, Vargas H, Walz J, Weber W, Wester H, Lecouvet F, Hicks R, Herrmann K, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, de Bono J, Fizazi K, Gillessen Sommer S, Gledhill S, Haberkorn U, Oyen W. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol 2018; 19:e696-e708.
01.12.2018Consensus on molecular imaging and theranostics in prostate cancer
01.12.2018Lancet Oncol 2018; 19:e696-e708
Fanti Stefano, Montironi Rodolfo, Ost Piet, O'Sullivan Joe M, Padhani Anwar R, Schalken Jack A, Scher Howard I, Tombal Bertrand, van Moorselaar R Jeroen A, Van Poppel Heindrik, Vargas Hebert Alberto, Walz Jochen, Weber Wolfgang A, Wester Hans-Jürgen, Lecouvet Frederic, Hicks Rodney J, Herrmann Ken, Minozzi Silvia, Antoch Gerald, Banks Ian, Briganti Alberto, Carrio Ignasi, Chiti Arturo, Clarke Noel, Eiber Matthias, de Bono Johann, Fizazi Karim, Gillessen Sommer Silke, Gledhill Sam, Haberkorn Uwe, Oyen Wim J G
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, Jonnada S, Gannon M, Gale J, Eswar C, Douis H, Din O, Birtle A, Bahl A, Khaksar S, Lester J, O'Sullivan J, Sydes M, Parmar M, Tran A, Srihari N, Sheehan D, Pudney D, Pedley I, Parikh O, Alonzi R, Amos C, Thalmann G, Chowdhury S, Attard G, Ritchie A, Ali A, Hoyle A, Clarke N, Brawley C, James N, Cross W, Dearnaley D, Gillessen Sommer S, Russell J, Millman R, Matheson D, Mason M, Malik Z, Langley R, Jones R, Gilson C, Parker C. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392:2353-2366.
21.10.2018Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
21.10.2018Lancet 2018; 392:2353-2366
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, Jonnada Sai, Gannon Melissa R, Gale Joanna, Eswar Chinnamani, Douis Hassan, Din Omar, Birtle Alison, Bahl Amit, Khaksar Sara, Lester Jason F, O'Sullivan Joe M, Sydes Matthew R, Parmar Mahesh K B, Tran Anna T H, Srihari Narayanan Nair, Sheehan Denise J, Pudney Delia M, Pedley Ian D, Parikh Omi A, Alonzi Roberto, Amos Claire L, Thalmann George N, Chowdhury Simon, Attard Gerhardt, Ritchie Alastair W S, Ali Adnan, Hoyle Alex P, Clarke Noel W, Brawley Christopher D, James Nicholas D, Cross William, Dearnaley David P, Gillessen Sommer Silke, Russell J Martin, Millman Robin, Matheson David, Mason Malcolm D, Malik Zafar I, Langley Ruth E, Jones Robert J, Gilson Clare, Parker Christopher C
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Saad F, O'Sullivan J, Federhofer J, Wirth M, Tucci M, Petrenciuc O, Nilsson S, Miller K, Lévy J, Gratt J, Heinrich D, Heidenreich A, Gillessen Sommer S, Carles J. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17:1306-16.
26.07.2016Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
26.07.2016Lancet Oncol 2016; 17:1306-16
Saad Fred, O'Sullivan Joe M, Federhofer Judith, Wirth Manfred, Tucci Marcello, Petrenciuc Oana, Nilsson Sten, Miller Kurt, Lévy Jérémy, Gratt Jeremy, Heinrich Daniel, Heidenreich Axel, Gillessen Sommer Silke, Carles Joan
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasilis V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol 2014; 10:219-31.
01.02.2014Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
01.02.2014Future Oncol 2014; 10:219-31
Molife L Rhoda, Pelling Katy, Temple Graham, Heath Catherine, Wheatley Duncan, Oommen Nikhil, Thompson Emilda, Jenkins Peter, Hickish Tamas, Pedley Ian, O'Sullivan Joe M, Olmos David, Fong Peter C, Lumsden Graeme, Bloomfield David, Karavasilis Vasilios, Jones Rob J, Omlin Aurelius, de Bono Johann S